CX DAILY

CX Daily: Sinovac’s Covid Fortune Fuels Bitter Boardroom Battle

Published: Jul. 24, 2025 9:20 a.m. GMT+8

00:00

00:00/00:00

Listen to this article 1x

TOP STORIES

Sinovac /

In Depth: Sinovac’s Covid fortune fuels bitter boardroom battle

The Covid-19 pandemic turned Chinese vaccine-maker Sinovac Biotech Ltd. into a global household name after its CoronaVac jab became a billion-dollar money spinner and one of the world’s most administered inoculations against the virus. But hidden away behind its success lies a bitter, decade-long power struggle for control of the company.

Register to read this article for free.

Register

Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.

Save an extra $50. Introductory offer for new readers. Subscribe now.

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Huaiyang Cuisine Takes Center Stage at Trump Banquet

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

China Business Uncovered Podcast: Inside Vanke and China’s Property Reckoning

00:00

00:00/00:00

MOST POPULAR

1: Cover Story: China’s AI Boom Is Rewiring Its Power Grid

2: China Auditor Exposes Local Governments Faking Debt Cleanups

3: Iran Clears Chinese Cargo Ships as Strait of Hormuz Sees Chaotic Reopening

4: China Rolls Out 15-Point Plan to Woo Foreign Capital

5: Chinese Business Group Urges EU to Ease New Foreign Investment Restrictions

SPONSORED

OR